NCT04827147

Clinical Trial of Multi-Periscopic Prism Glasses for Hemianopia

Active, enrolled NA Results posted Last updated 13 March 2026

What this trial tests

NA trial testing Multi-Periscopic Prism (MPP) glasses in Homonymous Hemianopia in 64 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

3 October 2022

Primary endpoint
30 April 2025

30 April 2026

Quick facts

Lead sponsor	Massachusetts Eye and Ear Infirmary
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	64
Start date	3 October 2022
Primary completion	30 April 2025
Estimated completion	30 April 2026
Sites	8 locations across United States

Drugs / interventions tested

• Multi-Periscopic Prism (MPP) glasses
• Fresnel Peripheral Prism (FPP) glasses

Conditions studied

• Homonymous Hemianopia — all drugs for Homonymous Hemianopia →

Sponsor

Massachusetts Eye and Ear Infirmary — full company profile →

Who can join

7 and older, any sex, with Homonymous Hemianopia. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Improvement in Blind-side Detection Rate for Hazards Approaching at a Bearing Angle of 40 Degrees Primary · Immediately after each 4-week intervention

Improvement in detection rate with prism glasses for hazards approaching from the blind side at a bearing angle of 40 degrees in the VR walking simulator test. Improvement is a binary outcome, defined as blind-side detection rate (number of pedestrians detected as a percentage of the total number of pedestrian events) which is significantly higher (z-test for two proportions) with than without prism glasses at the same visit.

Improved with MPPs

Group	Value	95% CI
All Participants Who Were Allocated	12

Improved with FPPs

Group	Value	95% CI
All Participants Who Were Allocated	10

Improvement in Blind-side Detection Rate for Hazards Approaching at a Bearing Angle of 20 Degrees Secondary · Immediately after each 4-week intervention

Improvement in detection rate with prism glasses for hazards approaching from the blind side at a bearing angle of 20 degrees in the VR walking simulator test. Improvement is a binary outcome, defined as blind-side detection rate (number of pedestrians detected as a percentage of the total number of pedestrian events) which is significantly higher (z-test for two proportions) with than without prism glasses at the same visit.

Improved with MPPs

Group	Value	95% CI
All Participants Who Were Allocated	14

Improved with FPPs

Group	Value	95% CI
All Participants Who Were Allocated	16

Device Preference Secondary · Immediately after the second 4-week intervention

Number of participants selecting each device as a percentage of the total number of participants enrolled

Preferred MPPs

Group	Value	95% CI
Participants Who Completed the Crossover	13

Preferred FPPs

Group	Value	95% CI
Participants Who Completed the Crossover	19

Sponsor's own description

This clinical trial will evaluate the efficacy of two types of high-power prism glasses that provide field of view expansion for patients with homonymous hemianopia (the complete loss of half the field of vision on the same side in both eyes).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Human retinal secretome: A cross-link between mesenchymal and retinal cells.
   Donato L, Scimone C, Alibrandi S, Scalinci SZ, et al · · 2023 · cited 6× · PMID 37545752 · DOI 10.4252/wjsc.v15.i7.665